Humedix hosts the Elravie Re2O Fine launch symposium, outlining precision ECM strategies for the periorbital area and neck
Humedix held the launch symposium for Elravie Re2O Fine, an ECM booster, in Seoul on June 24. Re2O Fine is a line extension of Re2O, the human acellular dermal matrix (hADM)-based skin booster launched last year that quickly gained traction in the market; with a finer mean particle size of about 50 µm, versus roughly 75 µm for standard Re2O, it targets thin, anatomically delicate areas such as the periorbital region and the neck. Lectures were delivered by Dr. Jeyoung Park of Apgujeong Oracle Dermatology, who also chaired the session, Dr. Hansaem Kim of DOD Dermatology Yongsan, and Dr. Jeongwoo Lee of ELEV Clinic. The three faculty discussed the implications of finer particles for particle count and contact surface area, combination with energy-based devices (EBDs), and region-specific mixing and injection protocols, and the subsequent panel discussion covered everything from why Re2O Fine warrants use as a distinct option to admixtures and combination treatment. Humedix said it would continue developing additional products and establishing treatment guidelines with Re2O Fine as the starting point, while releasing L&C Bio's clinical data on a rolling basis.
#MedicalAestheticNews #Humedix #ElravieRe2O #ElravieRe2OFine #DODDermatologyYongsan #DrHansaemKim #ApgujeongOracleDermatology #DrJeyoungPark #ELEVClinic #DrJeongwooLee
★ Article Link: https://www.medicalaestheticnews.com/news/articleView.html?idxno=20099




Comments
Post a Comment